Feature | September 06, 2007

Winning Combinations - Hybrids Make Imaging a One-Stop Shop

Winning Combinations - Hybrids Make Imaging a One-Stop Shop

Hybrids such as GE's Discovery VCT marry the high-speed, high-resolution capabilities of CT with the metabolic and physiologic capabilities of PET.

The continued merging of imaging modalities such as PET/CT, SPECT/CT and MR-PET enable clinicians to better integrate the benefits of complementary modalities. The benefits of these hybrids include faster acquisition times with increased performance in resolution and sensitivity. As these combined modalities enhance imaging for cardiology and oncology, clinicians are able to more accurately diagnosis disease, leading to better patient care and, in the long run, a reduced financial burden on healthcare.
According to Hadi Mougarrej, general manager of Molecular Imaging at GE Healthcare, “[Hybrids] have a clear benefit as one-stop shops in cardiac imaging.”
A key advantage of acquiring complete functional and anatomical data in one scan is that it avoids problems with repositioning a patient and co-registering in the case of acquiring both images separately. This makes it possible for less experienced doctors to achieve the same diagnostic accuracy as highly trained specialists.
“The key is being able to get all your information in a single visit,” said Jay Mazelsky, senior vice president and general manager of Nuclear Medicine at Philips Medical Systems.
“With SPECT/CT you can get comprehensive cardiac imaging in a single episode of care so you could do a true cardiac work-up by having both modalities, resulting in greater diagnostic confidence. Each modality has a best-in-class characteristic, so CT gives you the anatomical localization, while SPECT gives you some of the diagnostic confidence around metabolic function.”
According to Wm. Guy Weigold, M.D., director of Cardiac CT, Div. of Cardiovascular Disease at Washington Hospital Center (D.C.), hybrid imagers offer optimal viewing of the coronary vessels, as they are “rather torturous and complicated in the way they are laid out around the heart.”
“PET/CT is a great way to obtain cardiac functional data from the PET scan and then detailed anatomic information about the heart and the coronary arteries from the CT angiographic data,” he said.
MR-PET offers new insight into neurological disorders
While it is still undergoing research, MR/PET presents a tremendous leap forward in imaging by bringing the exceptional soft tissue contrast and high specificity of MR together with PET’s excellent sensitivity in assessing physiological and metabolic state.
“MR does soft tissue content as well as simultaneous data collection. When imaging a patient, that patient’s condition could change five minutes or even five seconds later. Being able to do PET and MR at exactly the same time can be an advantage,” said Mazelsky.
Researchers expect that MR-PET will open new doors in understanding the pathologies and progression of various neurological disorders like Alzheimer’s, Parkinson’s, epilepsy, depression and schizophrenia.
Cancer types identified and targeted
Nuclear medicine has traditionally focused on radiopharmaceuticals trapped in organ structures and the presence of disease hallmarked by the absence of activity. Exams are then followed with additional procedures, such as a biopsy, to determine the particular disease.
According to Mazelsky, molecular imaging with SPECT/CT offers a different view on traditional SPECT imaging, as newly developed SPECT tracers are target-specific, attracted only to the tissues they’ve been designed to find.
“With agents now entering the market you can actually diagnose a specific type of cancer such as prostate or bladder cancer as opposed to just cancer,” he said.
With MR/PET, clinicians may gain a more sound determination of both cognitive impairment and atrophy of diseases such as Alzheimer’s, as well as the ability to utilize neurological biomarkers. Similarly, MR/PET may allow physicians to study which brain tissues might be salvageable after a stroke.
“Ultimately, [MR/PET] will enable early treatment and highly personalized therapies,” said Lothar Spies, M.D., head of the Digital Imaging Department at Philips Research.
One stop means time and money saved
Hybrid modalities may also offer financial savings for both a hospital and a patient, as smaller numbers of staff will be needed for diagnosis.
“With hybrids you can make a diagnosis within a single episode,” said Mazelsky. “Instead of going to a nuclear medicine department and then to the department of radiology.”
According to Mazelsky, both Medicare and private payers may benefit financially from a hybrid, as some insurance will not reimburse for a second independent exam.
“The economic savings for [hybrids] really comes down to being able to get a diagnosis much quicker, without having to swim around looking for different possible causes of a patient’s condition,” said Mazelsky. <

Related Content

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
Cardiac MRI being performed at the DeBakey Heart Hospital.

Cardiac MRI being performed at the DeBakey Heart Hospital.

Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i